LSCI and Thermography in Diabetic Foot Patients Affected by Ulcer(s): (MY-FOOT-B)

Sponsor
Mario Negri Institute for Pharmacological Research (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05791929
Collaborator
(none)
82
36

Study Details

Study Description

Brief Summary

The objective of this observational study is to predict healing at 26 weeks after the first visit in patients affected by the first ulcer, by means of combined data monitoring of Laser Speckle Contrast Imaging (LSCI) and temperature measurements during patient visits in hospital.

In order to achieve this objective, study aims to produce a logistic regression model and then evaluate its prognostic ability by means of the area under the curve (AUC) of the receiver-operating-characteristics (ROC) curve.

Patients with diabetes mellitus and suffering from ulcer and receiving health care will undergo regular microcirculatory measurements including LSCI scans in and around the ulcer location and thermography.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The study aims to predict healing at 26 weeks after the first visit in patients affected by the first ulcer, by means of combined data monitoring of Laser Speckle Contrast Imaging (LSCI) and temperature measurements during patient visits in hospital.

    In order to achieve this objective, the study aims to produce a logistic regression model and then evaluate its prognostic ability by means of the area under the curve (AUC) of the receiver-operating-characteristics (ROC) curve.

    The variables evaluated for the model will include demographic and baseline characteristics of the patients, location and seriousness of the ulcer, alongside LSCI and temperature measurements at baseline and different timepoints. The development of the model will include a rigorous variables selection in order to produce a parsimonious model.

    In the method proposed by Mennes, LSCI measurements at baseline, biological zero, post occlusion peak, and other parameters like non-invasive blood pressure measurements were individually evaluated as possible prognostic factors of healing trajectory at 26 weeks. All these parameters, when assessed at their highest possible value of sensibility and specificity, produced AUCs always inferior to 0.65. The highest value of AUC (0.625) was reached by toe pressure parameter when calculated using a threshold value of 54 mmHg.

    From diagnostic literature, an AUC of ≥ 0.8 is considered excellent result, while an AUC < 0.7 is considered less than acceptable. Since the Mennes's method showed these results, study investigators set the AUC resulting from the model under the null hypothesis (H0) to be equal to 0.65. By including all these parameters, alongside the other mentioned variables, in a single prognostic model, study investigators expect to increase this prognostic ability. Therefore, in this study, investigators would like to detect an AUC ≥ 0.8 (H1). With these hypotheses, a power of 80%, a one-sided I type error of 5% and a prevalence of 43% of healed patients at 26 weeks, a total of 82 patients should be enrolled.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    82 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Image Features of LSCI and Thermography for Prediction of Healing Trajectory in Diabetic Foot Patients Affected by the First (or Successive) Ulcer: (MY-FOOT-B)
    Anticipated Study Start Date :
    Dec 1, 2023
    Anticipated Primary Completion Date :
    Jun 1, 2024
    Anticipated Study Completion Date :
    Dec 1, 2026

    Outcome Measures

    Primary Outcome Measures

    1. Area Under ROC curve generated by the statistical model able to discriminate between healing and not healing ulcers [at 26 weeks after the first visit in patients affected by the first ulcer]

      to discriminate between healing and not healing ulcers by means of combined data monitoring of Laser Speckle Contrast Imaging (LSCI) and temperature measurements during patient visits in hospital

    Secondary Outcome Measures

    1. The predictive positive and negative value related to the score test, based of calculation of likelihood ratio. [at 26 weeks after the first visit in patients affected by the first ulcer]

      The predictive positive and negative value related to the score test, based of calculation of likelihood ratio.

    2. The AUC of the models estimated according to different sites of ulcers. [at 26 weeks after the first visit in patients affected by the first ulcer]

      The AUC of the models estimated according to different sites of ulcers.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • a confirmed diagnosis of type 1 or type 2 diabetes mellitus (more than 5 years from diagnosis),

    • aged between 18 and 80 years,

    • patients affected by one foot ulcer (defined as break of the skin of the foot that involves at least the epidermis and part of the dermis )

    • signed informed consent.

    Exclusion Criteria:
    • having multiple foot ulcers,

    • having an amputation of the forefoot or an amputation at a more proximal location of the foot (e.g., midfoot or hindfoot),

    • severe foot infection (IWGDF grade 4),

    • being incapacitated or undergoing cancer treatment.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Mario Negri Institute for Pharmacological Research

    Investigators

    • Principal Investigator: Cesare Miranda, MD, Pordenone Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Mario Negri Institute for Pharmacological Research
    ClinicalTrials.gov Identifier:
    NCT05791929
    Other Study ID Numbers:
    • MY-FOOT-B
    First Posted:
    Mar 30, 2023
    Last Update Posted:
    Apr 3, 2023
    Last Verified:
    Mar 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Mario Negri Institute for Pharmacological Research
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 3, 2023